Ori Biotech

A London-headquartered company building automated machines and software that make cell and gene therapies faster and more affordable.

About Ori Biotech

Ori Biotech makes a manufacturing platform called IRO, which automates how cell and gene therapies are produced. It combines hardware, software and data services so that therapy developers can make their treatments at larger scale and lower cost.

Ori says it is on a "mission to enable widespread patient access to life-saving cell and gene therapies", and its chief executive says it is "making high-quality, affordable therapies a reality for more patients worldwide" (January 2025 release).

The company is headquartered in London and also has a base in the US. Its founders come from UCL (Dr Farlan Veraitch) and the advanced therapies industry (Professor Chris Mason). The exact London address and UK headcount were not in the pages we read.

The leadership team is drawn from pharma and manufacturing-equipment firms, and the company says that between them they have over 100 years of experience. That is the company's own claim.

We found no information on graduate schemes, internships or apprenticeships. It is a good example of an engineering-meets-biology company, so engineering, automation and bioprocess graduates may look at its careers page.

What they do

• {'desc': 'Automated, closed system for making cell and gene therapies.', 'title': 'IRO platform'}
• {'desc': 'Tools that track and improve manufacturing runs.', 'title': 'Software and data'}
• {'desc': 'Works with therapy developers and equipment firms.', 'title': 'Partnerships'}

Key facts

• Headquartered in London (January 2025 release)
• Founders: Prof Chris Mason and Dr Farlan Veraitch of UCL (company page)
• Platform called IRO (company releases)
• Chief executive Jason C. Foster (company page)

Website: www.oribiotech.com